Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone833-296-8268
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees45
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable
Axovant Gene Therapies (NASDAQ:AXGT) Frequently Asked Questions
What is Axovant Gene Therapies' stock symbol?
Axovant Gene Therapies trades on the NASDAQ under the ticker symbol "AXGT."
When did Axovant Gene Therapies' stock split? How did Axovant Gene Therapies' stock split work?
Shares of Axovant Gene Therapies reverse split on the morning of Wednesday, May 8th 2019. The 1-8 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 7th 2019. An investor that had 100 shares of Axovant Gene Therapies stock prior to the reverse split would have 13 shares after the split.
How were Axovant Gene Therapies' earnings last quarter?
Axovant Gene Therapies Ltd (NASDAQ:AXGT) announced its earnings results on Tuesday, June, 11th. The company reported ($0.45) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.70) by $1.25. View Axovant Gene Therapies' Earnings History.
When is Axovant Gene Therapies' next earnings date?
What price target have analysts set for AXGT?
9 brokerages have issued 12 month price targets for Axovant Gene Therapies' shares. Their forecasts range from $5.79 to $56.00. On average, they expect Axovant Gene Therapies' share price to reach $27.40 in the next year. This suggests a possible upside of 406.4% from the stock's current price. View Analyst Price Targets for Axovant Gene Therapies.
What is the consensus analysts' recommendation for Axovant Gene Therapies?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Gene Therapies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axovant Gene Therapies.
What are Wall Street analysts saying about Axovant Gene Therapies stock?
Here are some recent quotes from research analysts about Axovant Gene Therapies stock:
- 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (10/15/2019)
- 2. Cowen Inc analysts commented, ". We reiterate our Overweight rating and $221 Price Target. Amgen posted an strong top-line at $5.56B vs Bloomberg consensus of $5.51B and a bottom-line beat with EPS of $3.56 vs consensus of $3.49. This also included the ASR of $3B in 1Q 2019. Key update was raising of the low end of revenue and EPS guidance, so range is now $22.0-22.9B and $13.25-14.30/sh from $21.8-22.9B and $13.10-$14.30/sh previously based on 1Q results. Though the company noted this reflects a range of outcomes for Sensipar, this adjustment suggests it had been accounting for the potential for additional top-line pressure in 1Q." (5/1/2019)
- 3. HC Wainwright analysts commented, "Our price target of $7/share is based on an equally-weighted composite of: (a) $5.56/share, as a 35x multiple of taxed and diluted $1.70 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $9.23/ share (discounted cash flow analysis using a 15% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (3/12/2019)
Has Axovant Gene Therapies been receiving favorable news coverage?
Headlines about AXGT stock have been trending very negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Axovant Gene Therapies earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Axovant Gene Therapies.
Are investors shorting Axovant Gene Therapies?
Axovant Gene Therapies saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 930,700 shares, a decline of 7.9% from the August 30th total of 1,010,000 shares. Based on an average daily volume of 173,100 shares, the short-interest ratio is presently 5.4 days. Approximately 9.8% of the company's stock are sold short. View Axovant Gene Therapies' Current Options Chain.
Who are some of Axovant Gene Therapies' key competitors?
Some companies that are related to Axovant Gene Therapies include ChemoCentryx (CCXI), DiaMedica Therapeutics (DMCAF), Viking Therapeutics (VKTX), ImmunoGen (IMGN), Emisphere Technologies (EMIS), Intra-Cellular Therapies (ITCI), Homology Medicines (FIXX), OrganiGram (OGI), Retrophin (RTRX), Synthorx (THOR), BioDelivery Sciences International (BDSI), Progenics Pharmaceuticals (PGNX), Myovant Sciences (MYOV), Aprea Therapeutics (APRE) and Aurinia Pharmaceuticals (AUPH).
What other stocks do shareholders of Axovant Gene Therapies own?
Who are Axovant Gene Therapies' key executives?
Axovant Gene Therapies' management team includes the folowing people:
- Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)
- Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)
- Dr. David T. Hung M.D., Scientific Advisor of Group (Age 61)
- Dr. Fraser Wright, Chief Technology Officer
- Ms. Tricia Truehart, Head of Investor Relations
How do I buy shares of Axovant Gene Therapies?
Shares of AXGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Axovant Gene Therapies' stock price today?
One share of AXGT stock can currently be purchased for approximately $5.41.
How big of a company is Axovant Gene Therapies?
Axovant Gene Therapies has a market capitalization of $123.25 million. The company earns $-129,070,000.00 in net income (profit) each year or ($8.02) on an earnings per share basis. Axovant Gene Therapies employs 45 workers across the globe.View Additional Information About Axovant Gene Therapies.
What is Axovant Gene Therapies' official website?
How can I contact Axovant Gene Therapies?
Axovant Gene Therapies' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, 10036. The company can be reached via phone at 833-296-8268.
MarketBeat Community Rating for Axovant Gene Therapies (NASDAQ AXGT)
MarketBeat's community ratings are surveys of what our community members think about Axovant Gene Therapies and other stocks. Vote "Outperform" if you believe AXGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
